44 results about "Endometrial hyperplasia" patented technology

An improvement in a method of treating benign gynecological disorders is described. In the method, treatment of a benign gynecological disorder with a composition comprised of a gonadotropin releasing hormone (GnRH) compound and an estrogenic compound, and optionally, an androgenic compound, is extended to premenopausal women who are not receiving an exogenously supplied progestin on a regular or periodic basis. Treatment in accord with the invention does not increase significantly the risk of endometrial hyperplasia. The method is also suitable for contraception.

The invention discloses a minorcaliber tissue engineering artificial vessel. The excised extract cell umbilical vessel is taken as a bracket, the gap part of the bracket is filled with smooth muscle cells and mechanocyte; the endothelial progenitor cells or mesenchymal stem cells are planted in the surface of the inner wall of the excised extract cell umbilical vessel. The minorcaliber tissue engineering artificial vessel has good biocompatibility and has the abilities of inducing, supporting and maintaining cell functions, thus reducing the reciprocal infection of virus among seeds. The artificial vessel produced by the invention overcomes the problem that the supply of autologous vessel plantation is limited and the failure problem of the synthesized implants for formation of thrombosis and/or endometrial hyperplasia, thus improving the long transplantation patency that the minorcaliber tissue engineering artificial vessel is planted into human body, leading the sufferers to avoid a secondary operation. The raw materials of the artificial vessel are obtained easily, the preparation method is simple, and cost is low, thus being accepted by the sufferers and having vast social benefit and economic benefit.

The present invention discloses a coronary artery medicine coating scaffold for inhibiting endometrial hyperplasia and preventing restenosis in the scaffold. It includes dilating scaffold base body and inner coating layer coated on the dilating scaffold base body, the above-mentioned inner coating layer is formed from medicine carrier and ligustrazine, their mass ratio is 3:1-1:3, the above-mentioned inner coating layer is one of methyl acrylate, methyl methacrylate copolymer, polylactic acid, polyglycollic acid, polymonoracemic lactic acid, polylactide-diglycolide polymer, phosphorylcholine, ethyl polyurethane inorganic micropore aluminium oxide and cellulose or their composite.

The present invention belongs to the field of biomedical engineering, in the concrete, it relates to a photosensitive scaffold with the function of preventing and curing restenosis. The photosensitizer can be used to modify the scaffold so as to obtain photosensitive scaffold, said photosensitive scaffold is placed in the pathological lumen, and irradiated by light, so that the photosensitizer on the scaffold can be activated so as to produce photochemical reaction to form active oxygen substance, resist endometrial hyperplasia/and prevent production of scaffold restricture.

A kind of medicinal elution cardiovascular frame, comprises frame and biological degradation layer, which is made of biological degradation material that embeds the drug and covered in the frame. The characteristic is: the biological degradation material includes glycolide, L-lactide, homopolymers or one of the copolymer and the copolymer with polyfunctional group amino acid of Epsilon-caprolactone; the biological degradation layer contains the drug is a kind of macromolecule graft heparin. After the frame is implanted, the drug is deliveried to limit the endometrial hyperplasia sufficiently, and the heparin is exist continuously and steadily. It can prevent the occurrence of acute or subacute thrombus, and can promote the healing of the injury vessel wall, prevent the occurrence of late thrombus. Compare to the traditional heparin frame, it overcomes the defects like intolerance by the humor erosion and interceding poison substance in the progress of chemical binding.

A kind of medicinal elution cardiovascular frame, comprises saccule expansion frame and biological degradation layer, which is made of biological degradation material that embeds the drug and covered in the frame. Wherein, the biological degradation material includes glycolide, L-lactide, homopolymers or one of the copolymer and the copolymer with polyfunctional group amino acid of Epsilon-caprolactone. The biological degradation layer is a kind of macromolecule graft heparin, the drug contains rhubarb horsetails and one or more of the emodin. The biological degredation macromolecule graft heparin opposes being more narrow is covered in the frame. After the frame is implanted, the drug is deliveried to limit the endometrial hyperplasia sufficiently, and the heparin is exist continuously and steadily. It can prevent the occurrence of acute or subacute thrombus, and can promote the healing of the injury vessel wall, prevent the occurrence of late thrombus. Compare to the traditional heparin frame, it overcomes the defects like intolerance by the humor erosion and interceding poison substance in the progress of chemical binding.

The invention discloses application of cyanidin-3-O-glucoside in preparation of a medicine for treating and/or preventing an endometrial hyperplasia disease. The cyanidin-3-O-glucoside is found to becapable of improving endometrial hyperplasia and endometrial hyperproliferation caused by Cd exposure, and the cyanidin-3-O-glucoside intervenes in the process of protecting growth and development ofendometrial cells by maintaining the estrogen effect level, so that the uterus can normally grow, embryo implantation is ensured, and meanwhile, the cyanidin-3-O-glucoside has a protection effect on the endometrium. Therefore, the cyanidin-3-O-glucoside has a good application prospect in preparation of the medicine for treating and/or preventing the endometrial hyperplasia disease, preparation ofthe medicine for treating and/ or preventing Cd-induced abnormal proliferation of the endometrial cells and preparation of the medicine for protecting the endometrium.

The invention discloses an artificial blood vessel with a bias flow guide, and aims at solving the problem of terminal restenosis after a bridging operation. The artificial blood vessel consists of a common artificial blood vessel, a bias flow guide and a suturing edge which form a whole. The bias flow guide is characterized in that the through section gradually changes from a circle to a half ellipse, and the through section area is kept constant while the through section gradually deflects to the left side or the right side during the transition process, and the other side is filled with an artificial blood vessel material. The angle between the end face of the bias flow guide and the axis of the artificial blood vessel is 45 degrees which is typically adopted in the bridging surgery. The suturing edge is made of the artificial blood vessel material, and extends 1-2mm outwards for suturing the bridged blood vessel. The artificial blood vessel can cause a rotating flow in the bridged blood vessel, stabilizes blood stream and reduces turbulent flow, thus being more favorable to washing the internal wall of the bridged blood vessel, inhibiting occurrence of endometrial hyperplasia, and preventing the restenosis of the downstream terminal of the bridged part after the bridging operation.

A diet composition for use in the prevention and/or the treatment of endometrial hyperplasia in a human subject is provided. It has a) a fasting mimicking diet component to be administered for a first period of time and providing less than 50% of the normal caloric intake of the subject with both protein restriction and sugar restriction; and b) a re-feeding diet component to be administered for a second time period, which provides 60-100% of the normal caloric intake of the subject, wherein the fasting mimicking diet component and the re-feeding diet component are administered over multiple cycles.

The invention belongs to the field of traditional Chinese medicine (TCM), relates to a traditional Chinese medicine composition and a preparation method thereof, and specifically relates to a traditional Chinese medicine composition for the treatment of endometrial hyperplasia and a preparation method thereof. For overcoming the defects that existing chemotherapeutic drugs for endometrial hyperplasia are large in hepatotoxicity and poor in curative effect, the invention provides a traditional Chinese medicine composition for the treatment or prevention of endometrial hyperplasia, and the traditional Chinese medicine composition comprises the following components: 10-50 parts of herba leonuri, 10-20 parts of fructus ligustri lucidi, 5-20 parts of epimedium, 5-15 parts of cassia twig, 5-10 parts of radix achyranthis bidentatae, 5-15 parts of lotus leaves, 5-15 parts of honeysuckle, 1-10 parts of codonopsis pilosula, 5-15 parts of rhizoma anemarrhenae, 9-15 parts of caulis spatholobi, 9-15 parts of radix rehmanniae, 5-15 parts of folium artemisiae argyi, 1.5-9 parts of malaytea scurfpea fruits, 5.5-15 parts of semen cuscutae, 6-9 parts of fructus rosae laevigatae, and 10-15 parts of radix glycyrrhizae. The traditional Chinese medicine composition has a good treatment effect on the treatment or prevention of endometrial hyperplasia; and the traditional Chinese medicine composition has low drug side effects, and has significant clinical promotion value.

The invention discloses a traditional Chinese medicine composition for treating kidney deficiency and blood stasis type endometrial hyperplasia. The traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 40-50 parts of root of denseflower euonymus, 15-20 parts of root of redflower peasthrub, 20-25 parts of stem or leaf of fortune euonymus, 9-12 parts of flower of drooping stringbush, 15-20 parts of bulbil of common yam, 12-15 parts of root of franchet peashrub, 15-20 parts of root of stellaria yunnanensis, 15-20 parts of bark of Chinese ash, 6-12 parts of spinycalyx raspberry, 3-6 parts of cordyceps ophioglossoides, 30-40 parts of all-grass of sinuate tickclover, 6-9 parts of Chinese umbrellaleaf rhizome and root, 9-12 parts of herb of common pratia, 3-6 parts of herb of common corallodiscus, 9-12 parts of viola formosana hayata, 5-10 parts of nutgall and 5-7 parts of liquorice root. The traditional Chinese medicine composition disclosed by the invention has a high effective rate and reliable curative effects on treatment of kidney deficiency and blood stasis type endometrial hyperplasia, and cannot cause recurrence any more after healing.

The invention discloses a traditional Chinese medicine composition for treating endometrial hyperplasia caused by cold coagulation and blood stasis. The traditional Chinese medicine composition is characterized by being prepared from the following medicinal materials in parts by weight: 15-20 parts of desmodium triflorum, 1-3 parts of asarum wulingense, 1-3 parts of heartleaf saussurea root, 9-12 parts of sida szechuensis, 20-25 parts of christia constricta, 15-20 parts of rubus alceaefolius poir, 6-9 parts of paraquilegia, 12-15 parts of pratia nummularia, 10-20 parts of chelonopsis odontochila diels var.smithii(Kudo)C.Y.Wu,12-15 parts of common euscaphis fruit seeds, 6-10 parts of piper thomsonii, 10-15 parts of rubus pirifolicus smith, 5-10 parts of lethariella zahlbruckneria and 6-12 parts of allium splendens willd. The traditional Chinese medicine composition disclosed by the invention is used for treating endometrial hyperplasia caused by cold coagulation and blood stasis, and is high in effective rate, reliable in curative effect and free of recur after healing.

The invention relates to the field of biological medicine, and particularly discloses a nano-drug for inhibiting injured endometrial hyperplasia and application thereof. According to the invention, an anti-proliferation drug RAPA is used as a model drug, phenylboronic acid and mannose are used for synthesizing an amphiphilic carrier PBAP-CDI-Mannose (PCM) with ROS responsiveness, the amphiphilic carrier is used for entrapping the RAPA to form a nanoparticle PMR, and a macrophage cell membrane is coated on the nanoparticle PMR to prepare the multifunctional bionic nanoparticle MM-PMR. The bionic nano particle MM (at) PMR prepared by the invention is uniform in particle size, good in dispersity and relatively good in biocompatibility, has an immune escape function, can be used for targeted pathological site drug delivery, and can be used for inhibiting injured vascular intimal hyperplasia when being applied to preparation of drugs for treating vascular injury.

The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.

The invention discloses a traditional Chinese medicine composition for treating hypomenorrhea and infertility caused by thin endometrium and a preparation method thereof. The traditional Chinese medicine composition is prepared from 1-6 parts of roasted tortoise plastron, 1-6 parts of roasted turtle shell, 16 parts of prepared rehmannia root, 1-9 parts of pulp of dogwood fruit, 1-6 parts of parched white peony root, 0.5-3 part of fried angelica sinensis, 1-9 parts of ligusticum wallichii, 1.5-9 parts of spina date seed, 1-9 parts of roasted rhizoma anemarrhenae, 1-6 parts of poria cocos in Yunnan, 1-6 parts of fried codonopsis pilosula and 1-12 parts of roasted rhizoma atractylodis macrocephalae. A formula is screened through a large number of clinical researches, and a research result shows that the traditional Chinese medicine composition can effectively improve the syndromes of kidney yin deficiency type hypomenorrhea and infertility, increase the menorrhea, promote endometrial hyperplasia and follicle development in the later menstruation period, improve the levels of serum E2 and LH in the ovulation period, improve the levels of E2 and P in the middle luteal stage, increase the thickness of the endometrium in the middle-stage luteum, increase the volume of the endometrium and enrich blood perfusion under the endometrium in the middle-stage luteum, so that the endometrium receptivity is improved, embryo implantation is promoted to help pregnancy, and the traditional Chinese medicine composition is free of toxic and side effects and safe and reliable in medication.

The invention relates to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine preparation widely applied to gynecologic inflammation and a preparation method. The preparation is prepared from the following raw materials in parts by weight. Every 1L of olive oil contains 30-50g of cortex phellodendri and 50-70g of sophocarpidine, and the total amount ofoxygen introduced into every 1L of the olive oil is 20-24g at a temperature of 20-26 DEG C and a pressure of 0.5-1.5 bar. The preparation is simple to prepare, is used for people suffering from urinary tract infection caused by vaginitis, annexitis, mycoplasma, pelvic inflammation, chlamydia, cervical erosion, ovarian cyst, cervical polyp, hysteromyoma, endometritis, endometriosis, endometrial hyperplasia, functional uterine bleeding and the like, and is simple, convenient and rapid in curing. The preparation has no toxic or side effect exist, extremely high penetrating power, and no drug resistance.

The present application describes compounds according to Formula I, wherein Q, R¹, R² and X are described herein, that are useful as Estrogen Receptor Beta (ERβ) modulators. Additionally, the present application describes pharmaceutical compositions containing the compounds according to Formula I and optionally additional therapeutic agents. Finally, the present application describes methods utilizing the compounds according to Formula I for modulating the function of ERβ in the treatment of diseases and disorders associated with ERβ such as, for example, bone disorders; cardiovascular diseases; hypercholesterolemia; hypertriglyceridemia; vasomotor disorders; urogenital disorders; prostatic hypertrophy; endometrial hyperplasia; cancer and central nervous system disorders, such as, neurodegenerative disorders.